抗体药物市场－全球产业规模、份额、趋势、机会和预测：来源、产品、适应症、分销管道、地区和竞争格局（2021-2031年）

全球抗体医药品市场预计将从 2025 年的 793.6 亿美元大幅成长至 2031 年的 1,595.2 亿美元，复合年增长率为 12.34%。

抗体医药品是一种先进的生物疗法，由单株或多多株抗体组成，这些抗体经过基因工程改造，能够特异性结合抗原、中和病原体或调节免疫反应。该领域的发展主要受全球慢性疾病负担日益加重的驱动，例如自体免疫疾病和癌症。这些疾病需要标靶治疗，以期获得比传统小分子化合物更高的疗效和精准度。然而，临床开发过程中高昂的成本和复杂的生产过程构成了巨大的经济障碍，限制了其市场覆盖范围和可及性。

据抗体研究协会称，该领域的监管进展强劲，美国食品药物管理局（FDA）在2024年核准了15种新型抗体疗法。这一数字创下了该治疗方法在单一日历年内获批核准的最高纪录，凸显了该领域创新和接受度的加速发展。

市场驱动因素

全球癌症发生率的不断攀升是抗体医药品市场的主要驱动力，也因此迫切需要高度特异性的生物干预手段。随着癌症患者数量的增加，医疗机构越来越重视单株抗体，这类抗体能够选择性地攻击癌细胞，同时保护健康组织，与全身化疗相比，能够提供更优的治疗效果。根据国际癌症研究机构（IARC）2024年2月发布的新闻稿，预计2022年全球新增癌症病例将达到2,000万例，这印证了对有效治疗方法的巨大需求。患者数量的快速增长直接推动了重磅药物的商业性成功。例如，默克在2024年报告称，其单株抗体药物Keytruda的全球销售额在2023年成长了19%，达到250亿美元。

此外，产业领导者之间的策略联盟和授权协议正在加速抗体药物复合体（ADC）等下一代技术的研发，并推动市场扩张。製药公司正积极寻求高价值收购，以整合先进的工程平台并实现产品线多元化，同时避免内部研发所需的漫长週期。这一趋势促使企业对标靶连接子技术进行大量投资，以提高治疗的精准度。例如，强生公司于2024年1月宣布达成最终协议，将以约20亿美元收购Ambracs BioPharma，以加强其肿瘤产品组合。此类整合措施简化了从临床试验到商业化的流程，并扩大了尖端治疗方案的可近性。

市场挑战

临床研发的高昂成本和复杂的生产过程构成了巨大的财务壁垒，严重限制了全球抗体医药品市场的扩张。这些高昂的成本提高了进入门槛，实际上阻碍了中小型生物技术公司在没有外部支持的情况下将有前景的候选疗法推向市场。因此，该行业仍然由资金雄厚的大型公司主导，削弱了竞争活力，并维持了高定价模式，限制了全球患者的用药机会和报销途径。此外，生物製药生产固有的复杂性带来了额外的物流挑战和财务风险，抑制了对小众和高风险治疗领域的投资。

为了说明这些资金需求的规模，国际药品製造商协会联合会（IFPMA）估计，到2024年，开发一种新药的平均成本将达到26亿美元。如此庞大的资金需求迫使製药公司采取高度规避风险的研发管线策略，将资源集中在那些最有可能获得监管部门核准的化合物上。因此，这种财务压力限制了新型抗体医药品的研发管线，使投资集中在少数几个计划上，而不是治疗方法，减缓了市场整体成长速度。

市场趋势

双特异性和多特异性抗体平台的广泛应用，从根本上改变了治疗策略，使其能够同时抑制两种不同的疾病路径或将免疫细胞直接靶向肿瘤部位。这项技术进步使研发人员能够绕过单一特异性疗法通用的抗药性机制，从而在癌症和非癌症疾病中均获得更强效、更持久的疗效，进而提高患者的治疗依从性。这种方法的商业性可行性在眼科领域尤其显着。根据罗氏公司于2024年2月发布的2023年度报告，双特异性抗体Vabysmo的销售额预计将达到24亿瑞士法郎，证实了双标靶生物製剂在市场上的强劲需求。

另一个重要趋势是抗体疗法在神经退化性疾病领域的拓展，其治疗重点从缓解症状转向针对潜在病理（例如淀粉样蛋白和Tau）的疾病缓解疾病干预。这项进展需要开发专门的诊断和给药基础设施，从而为全球老龄化人口打造一个全新的、高附加价值的生物製药生产领域。Eisai正是这一趋势的体现。该公司在2024年8月的新闻稿中宣布，其阿兹海默症治疗药物Rekenvi在2024财年第一季的全球销售额达到63亿日圆。随着患者群体的不断扩大，这一数字环比增长显着。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球抗体药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依来源（人类单株抗体、人源化单株抗体、嵌合体抗体、鼠源单株抗体）
  • 副产品（单株抗体、抗体药物复合体）
  • 按适应症（癌症、自体免疫疾病、感染疾病、发炎性疾病、其他）
  • 按分销管道（医院药房、网路药房、零售药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美抗体药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲抗体药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗体药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲抗体药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美抗体药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球抗体药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie, Inc.
• ADC Therapeutics SA
• AstraZeneca PLC
• Genentech, Inc.
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Hiedelberg Pharma A/G
• Takeda Pharmaceutical Company Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Antibodies Drug Market is projected to expand significantly, rising from USD 79.36 Billion in 2025 to USD 159.52 Billion by 2031, reflecting a compound annual growth rate of 12.34%. Antibody drugs are sophisticated biological treatments consisting of monoclonal or polyclonal antibodies designed to specifically bind antigens, thereby neutralizing pathogens or modifying immune responses. Growth in this sector is primarily fueled by the increasing global burden of chronic diseases, such as autoimmune disorders and cancer, which demand the enhanced efficacy and precision provided by these targeted therapies over conventional small molecules. However, the substantial expenses involved in clinical development and the complex manufacturing processes create major financial hurdles that may limit market reach and accessibility.

According to The Antibody Society, regulatory progress in this field has been robust, with the US Food and Drug Administration approving 15 novel antibody-based therapeutics in 2024. This figure represents a record-breaking number of approvals for this specific therapeutic modality within a single calendar year, highlighting the accelerated pace of innovation and acceptance in the sector.

Market Driver

The rising global prevalence of cancer serves as a major driver for the antibodies drug market, creating an urgent need for highly specific biological interventions. As oncological caseloads grow, healthcare providers are increasingly favoring monoclonal antibodies that can selectively attack tumor cells while preserving healthy tissue, offering superior patient outcomes compared to systemic chemotherapy. Data from the International Agency for Research on Cancer in a February 2024 press release estimated 20 million new cancer cases globally in 2022, a statistic that underscores the immense demand for effective treatments. This surge in patient numbers directly drives the commercial success of blockbuster drugs; for instance, Merck & Co. reported in 2024 that global sales of its monoclonal antibody Keytruda increased by 19% to reach $25.0 billion for the full year 2023.

Furthermore, strategic partnerships and licensing deals among industry leaders are propelling market expansion by expediting the creation of next-generation technologies, such as antibody-drug conjugates. Pharmaceutical firms are actively pursuing high-value acquisitions to integrate advanced engineering platforms and diversify pipelines without enduring the lengthy timelines associated with internal discovery. This trend creates significant investment in targeted linker technologies to improve therapeutic precision, as demonstrated by Johnson & Johnson's January 2024 announcement regarding its definitive agreement to acquire Ambrx Biopharma for approximately $2.0 billion to bolster its oncology portfolio. Such consolidation efforts streamline the path from clinical trials to commercial launch, thereby widening access to cutting-edge therapeutic options.

Market Challenge

The substantial expenses linked to clinical development and the intricate nature of manufacturing processes pose a significant financial hurdle that severely limits the expansion of the global antibody drug market. These prohibitive costs establish a high barrier to entry, effectively preventing smaller biotechnology firms from bringing promising therapeutic candidates to market without outside assistance. As a result, the industry remains dominated by well-capitalized corporations, reducing competitive dynamics and maintaining high pricing models that restrict patient access and reimbursement opportunities worldwide. Additionally, the complexity inherent in biologic manufacturing introduces further logistical challenges and financial risks, thereby discouraging investment in niche or high-risk therapeutic areas.

Highlighting the magnitude of these financial demands, the International Federation of Pharmaceutical Manufacturers and Associations estimated in 2024 that the average cost to develop a new medicine stands at $2.6 billion. This immense capital requirement compels pharmaceutical companies to adopt highly risk-averse pipeline strategies, focusing resources only on compounds with the highest likelihood of regulatory approval. Consequently, this financial pressure restricts the pipeline of new antibody drugs and retards the overall pace of market growth, as investment is concentrated on a select few projects rather than a diverse range of potential therapies.

Market Trends

The widespread adoption of bispecific and multispecific antibody platforms is fundamentally reshaping treatment strategies by allowing for the simultaneous inhibition of two distinct disease pathways or the bridging of immune cells directly to tumor sites. This technological advancement enables developers to bypass resistance mechanisms common in monospecific therapies and enhances patient adherence by delivering more potent and durable responses across both oncological and non-oncological conditions. The commercial viability of this approach is evident in the ophthalmology sector; according to Roche's 2023 Annual Report released in February 2024, the bispecific antibody Vabysmo achieved sales of CHF 2.4 billion, confirming strong market acceptance for dual-targeting biologics.

Another critical trend is the expansion of antibody therapeutics into neurodegenerative diseases, shifting the focus from symptomatic relief to disease-modifying interventions that target underlying pathologies like amyloid and tau. This progression requires the development of specialized diagnostic and infusion infrastructure, establishing a new high-value segment for biological manufacturing tailored to an aging global population. This trajectory is illustrated by Eisai Co., Ltd., which reported in an August 2024 news release that global revenue for its Alzheimer's treatment Leqembi reached JPY 6.3 billion in the first quarter of fiscal year 2024, reflecting a substantial quarter-over-quarter growth as patient access continues to widen.

Key Market Players

• AbbVie, Inc.
• ADC Therapeutics SA
• AstraZeneca PLC
• Genentech, Inc.
• Genmab A/S
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Pfizer, Inc.
• Hiedelberg Pharma A/G
• Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global Antibodies Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibodies Drug Market, By Source

• Human mAb
• Humanized mAb
• Chimeric mAb
• Murine mAb

Antibodies Drug Market, By Product

• Monoclonal Antibodies
• Antibody-drug conjugates

Antibodies Drug Market, By Indication

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Inflammatory Diseases
• Others

Antibodies Drug Market, By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Antibodies Drug Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antibodies Drug Market.

Available Customizations:

Global Antibodies Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibodies Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Human mAb, Humanized mAb, Chimeric mAb, Murine mAb)
  • 5.2.2. By Product (Monoclonal Antibodies, Antibody-drug conjugates)
  • 5.2.3. By Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Antibodies Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Product
  • 6.2.3. By Indication
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antibodies Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Antibodies Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Antibodies Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By Distribution Channel

7. Europe Antibodies Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Product
  • 7.2.3. By Indication
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antibodies Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Antibodies Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Antibodies Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Antibodies Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Antibodies Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Antibodies Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Product
  • 8.2.3. By Indication
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antibodies Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Antibodies Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Antibodies Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Antibodies Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Antibodies Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Antibodies Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Product
  • 9.2.3. By Indication
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antibodies Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Antibodies Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Antibodies Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By Distribution Channel

10. South America Antibodies Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Product
  • 10.2.3. By Indication
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antibodies Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Antibodies Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Antibodies Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antibodies Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ADC Therapeutics SA
• 15.3. AstraZeneca PLC
• 15.4. Genentech, Inc.
• 15.5. Genmab A/S
• 15.6. Gilead Sciences, Inc.
• 15.7. GlaxoSmithKline PLC
• 15.8. Pfizer, Inc.
• 15.9. Hiedelberg Pharma A/G
• 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer